Relation between intestinal MICRObiota translocation and development of Graves Orbitopathy: the MICRO-GO study
Completed
- Conditions
- eyedisease associated with hyperthyreoidismGraves orbitopathy1004373910030061
- Registration Number
- NL-OMON41329
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
Caucasian subjects with Graves orbitopathy (males/postmenopauzal females, aged 18 to 69 years-old; and not on concomitant medication besides block/replacement therapy (thyrax en strumazol/PTU))
Exclusion Criteria
Use of prednisone/antibiotic in the last three months including proton pump inhibitors (PPI) is prohibited.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To determine differences in orbital tissue bacterial content and inflammatory<br /><br>genes expression is associated with clinical disease severity score (CAS) in<br /><br>Graves orbitopathy patients</p><br>
- Secondary Outcome Measures
Name Time Method <p>Differences in gutmicrobiota composition, mucosal integrity, subsequent<br /><br>endotoxemia and plasma levels of inflammation between subjects with low and<br /><br>high CAS scores in patients with Graves orbitopathy</p><br>